TD Cowen lowered the firm’s price target on Humacyte (HUMA) to $3.50 from $5 and keeps a Buy rating on the shares. The firm said the Symvess launch continues to advance with 13 hospital VAC approvals now in hand up from 5 in 1Q’25. Cowen said they are encouraged by this recent improvement in commercial traction and expect sequential revenue growth throughout 2H’25 and 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte’s Strategic Positioning and Growth Potential Justifies Buy Rating Despite Revenue Shortfall
- Humacyte price target lowered to $3 from $4 at H.C. Wainwright
- Humacyte Reports Q2 2025 Earnings and Market Expansion
- Buy Rating Reaffirmed for Humacyte Amid Promising Symvess Launch and Strategic Collaborations
- Humacyte reports Q2 EPS (24c), consensus (18c)